Literature DB >> 16317569

Oxymorphone: a review.

Eric Prommer1.   

Abstract

Oxymorphone (oxymorphone hydrochloride) (14-hydroxy-dihydromorphinone), a semisynthetic mu-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16317569     DOI： 10.1007/s00520-005-0917-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  27 in total

1.  Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study.

Authors:  Michael P Adams; Harry Ahdieh
Journal:  Pharmacotherapy       Date:  2004-04       Impact factor: 4.705

2.  Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets.

Authors:  Michael P Adams; Harry Ahdieh
Journal:  Drugs R D       Date:  2005

3.  Controlled release morphine tablets: a double-blind trial in patients with advanced cancer.

Authors:  G W Hanks; R G Twycross; J M Bliss
Journal:  Anaesthesia       Date:  1987-08       Impact factor: 6.955

4.  An evaluation of morphine and oxymorphone administered via patient-controlled analgesia (PCA) or PCA plus basal infusion in postcesarean-delivery patients.

Authors:  R Sinatra; K S Chung; D G Silverman; S J Brull; J Chung; D M Harrison; D Donielson; A Weinstock
Journal:  Anesthesiology       Date:  1989-10       Impact factor: 7.892

5.  The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain.

Authors:  Joseph Gimbel; Harry Ahdieh
Journal:  Anesth Analg       Date:  2004-11       Impact factor: 5.108

6.  Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.

Authors:  Paul Sloan; Neal Slatkin; Harry Ahdieh
Journal:  Support Care Cancer       Date:  2004-11-09       Impact factor: 3.603

7.  Leg edema from intrathecal opiate infusions.

Authors:  J A Aldrete
Journal:  Eur J Pain       Date:  2000       Impact factor: 3.931

8.  Intranasal absorption of oxymorphone.

Authors:  M A Hussain; B J Aungst
Journal:  J Pharm Sci       Date:  1997-08       Impact factor: 3.534

9.  Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer.

Authors:  W T Beaver; S L Wallenstein; R W Houde; A Rogers
Journal:  J Clin Pharmacol       Date:  1977-04       Impact factor: 3.126

Review 10.  Pharmacological treatment of cancer pain: alternative routes of opioid administration.

Authors:  C Ripamonti; E Zecca; F De Conno
Journal:  Tumori       Date:  1998 May-Jun
View more
  10 in total

1.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

3.  Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR.

Authors:  Xu Steven Xu; Mila Etropolski; David Upmalis; Akiko Okamoto; Rachel Lin; Partha Nandy
Journal:  Pharm Res       Date:  2012-05-23       Impact factor: 4.200

4.  Association of Physical Activity With Bioactive Lipids and Cardiovascular Events.

Authors:  Rosangela A Hoshi; Yanyan Liu; Mohit Jain; Daniel I Chasman; Olga V Demler; Samia Mora; Heike Luttmann-Gibson; Saumya Tiwari; Franco Giulianini; Allen M Andres; Jeramie D Watrous; Nancy R Cook; Karen H Costenbader; Olivia I Okereke; Paul M Ridker; JoAnn E Manson; I-Min Lee; Manickavasagar Vinayagamoorthy; Susan Cheng; Trisha Copeland
Journal:  Circ Res       Date:  2022-07-19       Impact factor: 23.213

5.  Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs.

Authors:  Lesley J Smith; Butch K Kukanich; Lisa A Krugner-Higby; Brynn H Schmidt; Timothy D Heath
Journal:  Vet Anaesth Analg       Date:  2013-04-20       Impact factor: 1.648

6.  Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.

Authors:  Tae Woo Park; Richard Saitz; Dara Ganoczy; Mark A Ilgen; Amy S B Bohnert
Journal:  BMJ       Date:  2015-06-10

Review 7.  Cancer Pain Management: Opioid Analgesics, Part 2.

Authors:  Rita J Wickham
Journal:  J Adv Pract Oncol       Date:  2017-09-01

8.  An organophotocatalytic late-stage N-CH3 oxidation of trialkylamines to N-formamides with O2 in continuous flow.

Authors:  Mark John P Mandigma; Jonas Žurauskas; Callum I MacGregor; Lee J Edwards; Ahmed Shahin; Ludwig d'Heureuse; Philip Yip; David J S Birch; Thomas Gruber; Jörg Heilmann; Matthew P John; Joshua P Barham
Journal:  Chem Sci       Date:  2021-12-28       Impact factor: 9.825

9.  Opioid dose and risk of suicide.

Authors:  Mark A Ilgen; Amy S B Bohnert; Dara Ganoczy; Matthew J Bair; John F McCarthy; Frederic C Blow
Journal:  Pain       Date:  2016-05       Impact factor: 7.926

Review 10.  Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.

Authors:  Amie L Severino; Arash Shadfar; Joshua K Hakimian; Oliver Crane; Ganeev Singh; Keith Heinzerling; Wendy M Walwyn
Journal:  Front Psychiatry       Date:  2018-04-23       Impact factor: 4.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.